Logo image of ALMKS.PA

MAKING SCIENCE GROUP SA (ALMKS.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALMKS - ES0105463006 - Common Stock

8.6 EUR
0 (0%)
Last: 1/16/2026, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ALMKS scores 2 out of 10 in our fundamental rating. ALMKS was compared to 69 industry peers in the Media industry. ALMKS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ALMKS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ALMKS has reported negative net income.
  • In the past year ALMKS had a positive cash flow from operations.
  • In the past 5 years ALMKS reported 4 times negative net income.
  • ALMKS had a positive operating cash flow in 4 of the past 5 years.
ALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

  • The Return On Assets of ALMKS (-0.99%) is worse than 68.75% of its industry peers.
  • ALMKS's Return On Equity of -6.62% is on the low side compared to the rest of the industry. ALMKS is outperformed by 68.75% of its industry peers.
  • With a decent Return On Invested Capital value of 7.51%, ALMKS is doing good in the industry, outperforming 67.19% of the companies in the same industry.
Industry RankSector Rank
ROA -0.99%
ROE -6.62%
ROIC 7.51%
ROA(3y)-2.49%
ROA(5y)-1.44%
ROE(3y)-23.01%
ROE(5y)-9.95%
ROIC(3y)N/A
ROIC(5y)N/A
ALMKS.PA Yearly ROA, ROE, ROICALMKS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

  • Looking at the Operating Margin, with a value of 1.86%, ALMKS is doing worse than 62.50% of the companies in the same industry.
  • ALMKS's Operating Margin has declined in the last couple of years.
  • ALMKS's Gross Margin of 20.80% is on the low side compared to the rest of the industry. ALMKS is outperformed by 79.69% of its industry peers.
  • In the last couple of years the Gross Margin of ALMKS has declined.
Industry RankSector Rank
OM 1.86%
PM (TTM) N/A
GM 20.8%
OM growth 3YN/A
OM growth 5Y-6.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.93%
GM growth 5Y-5%
ALMKS.PA Yearly Profit, Operating, Gross MarginsALMKS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

2

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ALMKS is creating some value.
  • Compared to 1 year ago, ALMKS has more shares outstanding
  • The number of shares outstanding for ALMKS has been increased compared to 5 years ago.
  • Compared to 1 year ago, ALMKS has an improved debt to assets ratio.
ALMKS.PA Yearly Shares OutstandingALMKS.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALMKS.PA Yearly Total Debt VS Total AssetsALMKS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • ALMKS has an Altman-Z score of 1.74. This is a bad value and indicates that ALMKS is not financially healthy and even has some risk of bankruptcy.
  • ALMKS has a Altman-Z score (1.74) which is comparable to the rest of the industry.
  • ALMKS has a debt to FCF ratio of 1140.00. This is a negative value and a sign of low solvency as ALMKS would need 1140.00 years to pay back of all of its debts.
  • ALMKS has a Debt to FCF ratio of 1140.00. This is in the lower half of the industry: ALMKS underperforms 67.19% of its industry peers.
  • A Debt/Equity ratio of 0.46 indicates that ALMKS is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.46, ALMKS is doing good in the industry, outperforming 60.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 1140
Altman-Z 1.74
ROIC/WACC1.1
WACC6.86%
ALMKS.PA Yearly LT Debt VS Equity VS FCFALMKS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • ALMKS has a Current Ratio of 0.76. This is a bad value and indicates that ALMKS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ALMKS has a worse Current ratio (0.76) than 71.88% of its industry peers.
  • ALMKS has a Quick Ratio of 0.76. This is a bad value and indicates that ALMKS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ALMKS has a worse Quick ratio (0.73) than 65.63% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.73
ALMKS.PA Yearly Current Assets VS Current LiabilitesALMKS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

6

3. Growth

3.1 Past

  • ALMKS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.58%, which is quite impressive.
  • ALMKS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.22%.
  • Measured over the past years, ALMKS shows a very strong growth in Revenue. The Revenue has been growing by 51.26% on average per year.
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-323.33%
Revenue 1Y (TTM)16.22%
Revenue growth 3Y35.39%
Revenue growth 5Y51.26%
Sales Q2Q%21.45%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.62% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 22.10% on average over the next years. This is a very strong growth
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALMKS.PA Yearly Revenue VS EstimatesALMKS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ALMKS.PA Yearly EPS VS EstimatesALMKS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALMKS. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 35.13, which means the current valuation is very expensive for ALMKS.
  • Based on the Price/Forward Earnings ratio, ALMKS is valued a bit more expensive than the industry average as 62.50% of the companies are valued more cheaply.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, ALMKS is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 35.13
ALMKS.PA Price Earnings VS Forward Price EarningsALMKS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

  • ALMKS's Enterprise Value to EBITDA ratio is in line with the industry average.
  • Based on the Price/Free Cash Flow ratio, ALMKS is valued a bit more expensive than the industry average as 67.19% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 1544.56
EV/EBITDA 9.36
ALMKS.PA Per share dataALMKS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • ALMKS's earnings are expected to grow with 15.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.46%
EPS Next 3Y15.62%

0

5. Dividend

5.1 Amount

  • ALMKS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

MAKING SCIENCE GROUP SA

EPA:ALMKS (1/16/2026, 7:00:00 PM)

8.6

0 (0%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)07-31
Earnings (Next)N/A
Inst Owners3.56%
Inst Owner ChangeN/A
Ins Owners61.03%
Ins Owner ChangeN/A
Market Cap77.23M
Revenue(TTM)274.00M
Net Income(TTM)-1.72M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 35.13
P/S 0.28
P/FCF 1544.56
P/OCF 234.02
P/B 2.97
P/tB N/A
EV/EBITDA 9.36
EPS(TTM)-0.2
EYN/A
EPS(NY)0.24
Fwd EY2.85%
FCF(TTM)0.01
FCFY0.06%
OCF(TTM)0.04
OCFY0.43%
SpS30.51
BVpS2.9
TBVpS-4.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.99%
ROE -6.62%
ROCE 10.22%
ROIC 7.51%
ROICexc 13.46%
ROICexgc N/A
OM 1.86%
PM (TTM) N/A
GM 20.8%
FCFM 0.02%
ROA(3y)-2.49%
ROA(5y)-1.44%
ROE(3y)-23.01%
ROE(5y)-9.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-6.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.93%
GM growth 5Y-5%
F-Score6
Asset Turnover1.58
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 1140
Debt/EBITDA 1.03
Cap/Depr 4.29%
Cap/Sales 0.1%
Interest Coverage 1.14
Cash Conversion 2.84%
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.73
Altman-Z 1.74
F-Score6
WACC6.86%
ROIC/WACC1.1
Cap/Depr(3y)13.72%
Cap/Depr(5y)311.76%
Cap/Sales(3y)0.4%
Cap/Sales(5y)7.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-323.33%
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue 1Y (TTM)16.22%
Revenue growth 3Y35.39%
Revenue growth 5Y51.26%
Sales Q2Q%21.45%
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A
EBIT growth 1Y278.77%
EBIT growth 3YN/A
EBIT growth 5Y41.58%
EBIT Next Year200%
EBIT Next 3Y56.86%
EBIT Next 5YN/A
FCF growth 1Y103.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y178.57%
OCF growth 3Y-64.23%
OCF growth 5YN/A

MAKING SCIENCE GROUP SA / ALMKS.PA FAQ

What is the fundamental rating for ALMKS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALMKS.PA.


Can you provide the valuation status for MAKING SCIENCE GROUP SA?

ChartMill assigns a valuation rating of 0 / 10 to MAKING SCIENCE GROUP SA (ALMKS.PA). This can be considered as Overvalued.


What is the profitability of ALMKS stock?

MAKING SCIENCE GROUP SA (ALMKS.PA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for MAKING SCIENCE GROUP SA?

The Earnings per Share (EPS) of MAKING SCIENCE GROUP SA (ALMKS.PA) is expected to decline by -27.27% in the next year.